Clinical Trial

Trial Protocol ID USOR 24232_NVL-655-04_ALKAZAR *STAR*

Trial Description

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR) (NVL-655-04)

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Disease Types

Sponsors

  • Nuvalent, Inc.
  • PPD, Inc.